Physician profile
Michael D Harris
NPI 1740427079
$4,164.29
in general payments reported to CMS, 2019-2025
24 companies · $873 in 2025
The $873 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $220 · 2021: $344 · 2022: $429 · 2023: $645 · 2024: $822 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,340.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,270.36 | 2019-2025 | Axios, Exalt Model D, Overstitch Endoscopic Suturing System |
| Abbvie INC. | $1,125.15 | 2019-2025 | |
| Covidien Lp | $371.04 | 2019 | |
| Mallinckrodt Hospital Products INC. | $356.47 | 2024 | Terlivaz |
| Medtronic, INC. | $207.04 | 2022-2025 | Dragonfly Pancreaticobiliary Scope and Instrument Channel Caps |
| Janssen Biotech, INC. | $176.40 | 2022-2023 | Stelara, Simponi, Remicade |
| Aimmune Therapeutics, INC. | $118.89 | 2024-2025 | Vowst, Zenpep |
| Vivus LLC | $58.01 | 2021-2025 | Pancreaze |
| Amgen INC. | $50.64 | 2025 | Uplizna |
| Intuitive Surgical, INC. | $49.75 | 2019 | |
| Genzyme Corporation | $45.22 | 2025 | |
| Baxter Healthcare | $42.29 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.77 | 2019-2023 | Recarbrio, Zinplava, Dificid |
| Lumendi LLC | $36.90 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.93 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $32.10 | 2023 | Dat Closure Device |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.26 | 2021-2022 | |
| Lilly USA, LLC | $28.99 | 2024 | Omvoh |
| Conmed Corporation | $23.92 | 2025 | Conmed Biliary |
| Qol Medical, LLC | $22.84 | 2021 | |
| Dynavax Technologies Corporation | $18.14 | 2021 | |
| Csl Behring | $16.73 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.45 | 2023 | Givlaari |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.